Bonesupport Holding AB (publ) announces strong results in an Australian study on the treatment of bone infection due to diabetic foot ulcers. The study results show an amputation rate of 2% when using CERAMENT® G or CERAMENT® V, which is significantly lower than the control group at 18% who received standard treatment. The results are in line with previously published studies from Europe.

The study results show that the use of CERAMENT G or CERAMENT V not only significantly reduces the risk of amputation and surgical interventions but also promotes effective healing and shorter hospital stays compared to the control group receiving conventional treatment. The number of hospital days was 12.6 compared to 25.1 for the control group.